Impact of reactogenicity on quality of life and physical functioning in adults ≥50 years receiving both doses of the adjuvanted recombinant zoster vaccine

Authors
Category Primary study
JournalOpen Forum Infect. Dis.
Year 2019
This article has no abstract
Epistemonikos ID: eb1db7614444884541864e2b286dc21ac50d29a4
First added on: May 09, 2021